The multi-year deal involves the two companies working together to engage patients and caregivers at every stage of their journey.
Genetic risk reports for Alzheimer's disease, Parkinson's disease and Hereditary Thrombophilia included in the FDA authorization, among others.
The application enables clinicians all around the world to make rare and genetic disease discoveries using deep learning and artificial intelligence.
The Culver City, California-based company has developed a platform, called CLINICS, to address many of the key challenges healthcare constituents face.
Vitruvian Networks, will serve as a network orchestrator for therapeutic companies with powerful business intelligence and data analytics capabilities.
Called GADGET-PD, the trial will use wireless sensors and genetic sequencing to determine if a patient has essential tremor (ET) from Parkinson's disease (PD).
Researchers are now able to design targeted studies for diseases and conditions, and to gather more specific types of data from participants.
Knome's knoSYS tech brings maximum value to the already robust genome informatics offerings at Tute, used by many of the top institutions across the world.
Called Personal Genome Service, it is touted as an entirely new experience that includes carrier status, wellness, trait and ancestry reports.
The new funds will help the personal genetics company launch new global user experience, grow its sales efforts and therapeutics discovery group efforts.